Everything below concerns Reverse-phase HPLC. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-07-15. Where a claim depends on a specific study, the study is described rather than over-claimed.
Peptide bonds are susceptible to hydrolysis under extreme pH and to enzymatic cleavage if proteases are present. Heat, oxidising agents, and prolonged exposure to light also contribute to loss of material. Aggregation can occur at high concentrations or in certain buffer systems, and it may not be visible to the eye. Storage at -20 C or below is typical for both powder and aliquoted solutions, and desiccation of the powder is preferred.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography together with mass spectrometry. The chromatogram provides a purity estimate as a percentage of total peak area, while the mass spectrum confirms that the observed mass matches the expected value. Amino acid analysis or tandem mass spectrometry sequencing can provide additional confirmation. Reported purity figures depend on the column, gradient, and detection wavelength, so values from different laboratories are not directly comparable without method details.
Lyophilised peptide is normally reconstituted with sterile water or a neutral buffer shortly before use. Because repeated freeze-thaw cycles can degrade the material, dividing a reconstituted solution into single-use aliquots is a common practice. Working solutions are usually kept cold and protected from light. The exact shelf life depends on concentration, buffer composition, and handling, so it is often determined empirically rather than assumed.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
| Property | Value | Notes |
|---|---|---|
| Purity determination | Reversed-phase HPLC | UV detection commonly at 214 nm |
| Mass confirmation | Mass spectrometry | Compared against theoretical 888.5 Da |
| Powder storage | -20 C or below | Dry and protected from light |
| Reconstituted storage | Aliquoted and frozen | Avoid repeated freeze-thaw cycles |
| Reconstitution solvent | Sterile water or neutral buffer | Avoid extreme pH conditions |
Lyophilized peptide powder is normally held desiccated at −20 °C, with −80 °C used for longer storage periods. Allowing a sealed vial to reach room temperature before opening is standard practice, because condensation forming on cold powder introduces moisture. Once dissolved, solutions are typically kept cold and shielded from light. Repeated freeze-thaw cycles are avoided because they encourage aggregation and gradual loss of material. These conventions are general to synthetic peptides rather than unique to any one sequence.
Purity and identity are separate measurements and are often confused. Reverse-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, reports the share of total peak area belonging to the target compound. Mass spectrometry by electrospray or matrix-assisted laser desorption then checks whether the observed mass matches the expected sequence. Neither measurement alone shows that a vial holds the intended peptide. Peptide content, meaning the fraction of vial mass that is genuine peptide rather than counter-ion, water or residual acid, is reported separately and is frequently lower than the stated purity figure.
The regulatory position is broadly consistent across major jurisdictions: no thymosin beta-4 fragment is an approved medicine, and laboratory material is commonly labelled as not intended for human consumption. Anti-doping rules in sport list thymosin beta-4 and its fragments among prohibited peptide hormones. Because these products travel through research-chemical channels rather than pharmaceutical supply chains, quality varies considerably between vendors. Independent testing of identity, purity and sterility is the only dependable check, and a certificate of analysis describes one batch rather than a supplier's whole catalogue.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Concept had a remake by Felix Wankel, a self-taught tightness specialist, never had an engineer diploma, neither a driver's license, for the Torpedo engine Jumo KM-8. Itala (company) succeeded in a different type of Rotary Valve. In Britain, the National Engine Company Ltd advertised its rotary valve engine for use in early aircraft, at a time when poppet valves were prone to failure by sticking or burning. In the end of 1930s, Frank Aspin developed a design with a rotary valve that rotated on the same axis as the cylinder bore, but with limited success. US company Coates International Ltd has developed a spherical rotary valve for internal combustion engines which replaces the poppet valve system. This particular design is four-stroke, with the rotary valves operated by overhead shafts in lieu of overhead camshafts (i.e. in line with a bank of cylinders). The first sale of such an engine was part of a natural gas engine-generator. Rotary valves are potentially highly suitable for high-revving engines, such as those used in racing sportscars and F1 racing cars, on which traditional poppet valves with springs can fail due to valve float and spring resonance and where the desmodromic valve gear is too heavy, large in size and too complex to time and design properly. Rotary valves could allow for a more compact and lightweight cylinder head design. They rotate at half engine speed (or one quarter) and lack the inertia forces of reciprocating valve mechanisms. This allows for higher engine speeds, offering approximately perhaps 10% more power.
A protein-sorting transpeptidase is an enzyme, such as the sortase SrtA of Staphylococcus aureus, that cleaves one or more target proteins produced by the same cell, as part of a specialized pathway of protein targeting. The typical prokaryotic protein-sorting transpeptidase is characterized as a protease, but does not simply hydrolyze a peptide bond. Instead, the larger, N-terminal portion of the cleaved polypeptide is transferred onto another molecule, such as a precursor of the peptidoglycan cell wall in Gram-positive bacteria. The term sortase is properly reserved for the set of cysteine protease enzymes sortase A, sortase B, and members of additional classes, all of which share homology. However, a growing number of additional protein sorting systems has been described in prokaryotes, involving sorting enzymes that lack any homology to sortase and that appear to have arisen separately by convergent evolution. Although the sortases are the best described members of the protein-sorting transpeptidases, work on the analogous enzymes archaeosortase, rhombosortase, and the PorU enzyme of type IX secretion systems (T9SS) has been accumulating.
==== Blue MX-R ==== Blue MX-R or Reactive Blue 4 has a formula of C23H14Cl2N6O8S2 and a molecular weight of 637.4 g/mol. It contains dichlorotriazine ring to the chromophore unlike Cibacron Blue F3GA. For a large scale protein purification, Blue MX-R can be used to purify protein such as lactate dehydrogenase (LDH). In fast-protein liquid chromatography (FPLC) using Blue MX-R immobilized on poly(glycidyl methacrylate-co-ethylene dimethacrylate) beads, it was seen to separate lysozyme and bovine serum albumin (BSA), purified lysozyme from chicken albumin.
Sources: en.wikipedia.org
== Research career == Mary Osborn carried out postdoctoral research from 1967 to 1969 in the laboratory of James Watson at Harvard University. Then she conducted research at the Laboratory of Molecular Biology, Cambridge, UK (1969–72) before moving to the Cold Spring Harbor Laboratory (1972-75.) Osborn had married her husband, Klaus Weber, on 14 July 1972. Weber and Osborn moved to the Göttingen Max Planck Institute for Biophysical Chemistry where Weber was Director and Osborn received a staff appointment in 1975. in 1989, she was appointed an honorary professor at University of Göttingen.
=== Fourth representation === The fourth version of the thermospray vaporizer heats the capillary tube only by direct DC/AC ohmic (Joule) heating. A thermocouple placed in thermal contact with the exit of the capillary is used to prevent the destructive thermal runaway caused by overheating. This representation was concluded to be the ideal design by the 1988 patent.
For services to the Arts and to the community in Southend-on-Sea, Essex. Dr. Alasdair Cunningham Bruce. Boston Spa Renewed Programme Manager. For services to Libraries. Christopher John Paul Bryant. Director of Tournaments and Events, Football Association. For services to Sport. Jennifer Sheridan Bryer. Teacher, Pony Club. For services to Horse Riding. Peter George Buchan. Managing Director, Shipping, Nuclear Transport Solutions. For services to the Nuclear Industry and to Young People. Khumi Tonsing Burton, JP, DL. For services to the community in Manchester and Cheshire. Ronald Butler. Policy Adviser, Department for Work and Pensions. For services to Disadvantaged People. Carrie Byrom. Director, Stable Lives. For services to Mental Health and the community in North West England. David Corrie Calvert. President, Langholm Town Band. For services to the community in Langholm, Dumfries. Carl Campbell. Founder and Artistic Director, CCDC7. For services to African Caribbean Dance Education and Culture. Catriona Yvonne Fiona Campbell. UK&I Chief Technology and Innovation Officer, EY. For services to Technology and Innovation. George Alan Carney. Executive Officer, Department for Education. For Public Service. Professor Kathryn Janice Carruthers. Professor of French Linguistics, Queen's University Belfast. For services to Modern Languages. Kathryn Melanie Keele Caton. Founder and Managing Director, Brighton Gin. For services to Trade and to the community in Brighton. Amanda Chadwick. Founder and Trustee, Pyjama Fairies. For services to Children in Hospital. Edward Kay Kiu Chan.
Sources: en.wikipedia.org
The lyophilised powder is typically held at -20 C or lower in a dry, dark place. Reconstituted solutions are aliquoted and frozen to avoid repeated freeze-thaw cycles.
Mass spectrometry is the usual confirmatory method because it measures the intact mass. Reversed-phase chromatography is used alongside it to estimate purity.
Not directly. Reported percentages depend on the chromatographic method, detection wavelength, and integration criteria, so the underlying method details matter.
TB-500 is a synthetic heptapeptide corresponding to a fragment of thymosin beta-4. It is used in laboratory research and is not an approved drug.